Pay in 4 interest-free payments of $5.51 Learn more
Ships within 48 hours · Estimated delivery Aug 28 - Sep 2
Related MSH Analogues Peptides
221 (2), e201911005
Key Highlights: Primary endpoint met: ~1.72.0% A1C reduction at 40 weeks vs ~0.8% placebo Significant weight loss: ~1517% reduction vs ~2.5% placebo Sustained efficacy: No weight-loss plateau observed over study duration Triple mechanism: Targets GLP-1, GIP & glucagon receptors for amplified metabolic effects Convenient dosing: Once-weekly injectable therapy Why It Matters: Beyond GLP-1: Signals the shift to multi-hormone incretin therapies Dual efficacy: Combines deep A1C reduction + substantial weight loss Competitive edge: Strengthens Lillys position vs semaglutide & tirzepatide Holistic impact: Potential to improve broader cardiometabolic outcomes Key Takeaway: Retatrutide is emerging as a potential best-in-class metabolic therapy, combining powerful glucose lowering with significant weight loss
Gonzalez-Mariscal L, Tapia R, Chamorro D (2008) Crosstalk of tight junction components with signaling pathways
Vendors should disclose temperature-controlled storage
